Tetra Bio-Pharma and Neptune to Co-Develop Cannabinoid Oil Products

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) and Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NEPT) announced a new agreement for the development of purified cannabinoid oil-based products related to pain and inflammation reduction in both the natural health products and pet veterinary markets.

As quoted in the press release:

“We are proud to partner with a company like Neptune. Their know-how in extraction, performed in a state of the art GMP facility, is a great asset to have for the cannabis medicinal/pharma oil market. This combined to Tetra’s expertise in the development of products for the prescription drug and pharma retail market, makes this partnership truly one of a kind. Leveraging our complementary expertise in research, regulatory affairs, science, formulation, and delivery forms, we intend to commercialize these new products in preparation of the forthcoming retail cannabis market in Canada, and a RX veterinary North American market,” stated Bernard Fortier, Chief Executive Officer (CEO) of Tetra.

”We are excited to partner with Tetra, a biopharmaceutical leader in the development of cannabinoid-based novel drugs and treatments. The products that will be co-developed will be supported by research as well as our unique formulation and delivery system knowledge, which are key components of our mission to deliver differentiated science-based, value-added products,” said Jim Hamilton, President and CEO of Neptune.

Click here to read the full press release.

Source: www.marketwired.com